Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight

globenewswire.com
LLY Eli Lilly's drug ZEPBOUND (tirzepatide) received FDA approval for moderate-to-severe OSA in adults with obesity, marking a significant pharmacological advancement. The drug's efficacy is driven by weight reduction, addressing a key factor in OSA. RMD ResMed is mentioned as a key player in the sleep apnea devices market. The article discusses the broader competitive landscape and market trends without specific sentiment towards ResMed's current performance or future prospects. PHG Koninklijke Philips N.V. is listed as a key company in the sleep apnea devices market. The article provides a general overview of the market and competitive landscape, without specific sentiment towards Philips. VIVO Vivos Therapeutics, Inc. is mentioned as a company in the sleep apnea devices market. The article focuses on the broader market and competitive landscape, not providing specific sentiment for Vivos.

Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight New York, USA, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight

The obstructive sleep apnea competitive landscape report delivers important insights into approved as well as ongoing research on 22+ pipeline obstructive sleep apnea drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s Obstructive Sleep Apnea Competitive Landscape and Clinical Trial Analysis 2026 report provides comprehensive global coverage of approved and pipeline obstructive sleep apnea therapies across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the obstructive sleep apnea therapeutics domain.

Key Takeaways from the Obstructive Sleep Apnea Pipeline Report

Request a sample and discover the recent developments in the obstructive sleep apnea treatment @ https://www.delveinsight.com/report-store/obstructive-sleep-apnea-competitive-landscape-and-clinical-trial-analysis

What is Obstructive Sleep Apnea?

Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder characterized by repeated episodes of partial or complete blockage of the upper airway during sleep. These obstructions can temporarily stop or reduce airflow, causing intermittent drops in blood oxygen levels and frequent brief awakenings as the body attempts to restore normal breathing. Common symptoms include loud snoring, witnessed pauses in breathing, gasping or choking during sleep, morning headaches, excessive daytime sleepiness, and difficulty concentrating. OSA is associated with factors such as obesity, increasing age, enlarged tonsils or other anatomical airway features, and certain lifestyle and medical conditions. If left untreated, persistent OSA can contribute to cardiovascular and metabolic complications and negatively affect daytime functioning and quality of life.

To know more about obstructive sleep apnea, visit @ Obstructive Sleep Apnea Therapies

Approved Obstructive Sleep Apnea Drug Profile Analysis

ZEPBOUND: Eli Lilly and Company

ZEPBOUND (tirzepatide), developed by Eli Lilly and Company, is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. By stimulating both GIP and GLP-1 receptors, the drug helps suppress appetite and reduce food intake, resulting in substantial weight loss. In obstructive sleep apnea (OSA), tirzepatide’s therapeutic benefit is primarily driven by weight reduction, which may alleviate upper-airway obstruction during sleep and reduce the frequency of apnea and hypopnea episodes. In December 2024, the U.S. FDA approved tirzepatide for adults with obesity and moderate-to-severe OSA, marking the first FDA-approved pharmacological treatment specifically indicated for OSA.

Find out more about what's the best pharma company offering obstructive sleep apnea medications @ Obstructive Sleep Apnea Drugs

A snapshot of the Pipeline Obstructive Sleep Apnea Drugs mentioned in the report:

Learn more about the emerging obstructive sleep apnea therapies @ Obstructive Sleep Apnea Clinical Trials

Arunima Dabral, Assistant Project Manager of Competitive Intelligence and Consulting at DevleIsnight, said that the OSA therapeutics landscape is evolving beyond traditional device- and lifestyle-based management toward a more diversified pharmacological paradigm targeting metabolic, neuromuscular, airway-control, and cardiometabolic mechanisms. Late-stage development of dual incretin and GLP-1 receptor agonists is strengthening weight-loss-mediated treatment, while norepinephrine reuptake inhibition combined with muscarinic receptor antagonism provides a more direct approach to improving upper-airway patency. Emerging mechanisms, including carbonic anhydrase inhibition with cannabinoid receptor modulation, aldosterone synthase inhibition, and potassium channel inhibition, delivered through oral, subcutaneous, and intranasal routes, further underscore this diversification. Overall, the future outlook points toward a more personalized treatment paradigm combining weight management, metabolic intervention, neuromuscular modulation, and locally acting approaches, with efficacy, durability, safety, adherence, patient selection, and the ability to achieve clinically meaningful OSA control comparable with established standards of care expected to determine their adoption and positioning.

Recent Developments in the Obstructive Sleep Apnea Treatment Space

Scope of the Obstructive Sleep Apnea Pipeline Report

Dive deep into rich insights for new treatments for obstructive sleep apnea, visit @ Obstructive Sleep Apnea Medications

Table of Contents

For further information on the obstructive sleep apnea pipeline therapeutics, reach out @ Obstructive Sleep Apnea Therapeutics

Related Reports

Obstructive Sleep Apnea Market

Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obstructive sleep apnea companies, including Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc., Apnex Medical Inc., and others.

Obstructive Sleep Apnea Pipeline

Obstructive Sleep Apnea Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key sleep apnea companies, including Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science, and others.

Sleep Apnea Market

Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sleep apnea companies, including Apnimed, Eli Lilly and Company, Incannex Healthcare, and others.

Sleep Apnea Devices Market

Sleep Apnea Devices Market Insights, Competitive Landscape and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key sleep apnea devices companies, including Koninklijke Philips N.V., ResMed, Fisher & Paykel Healthcare Limited, and AMBULANCE (SHENZHEN) TECH. CO. LTD, BMC, Beijing Aeonmed Co., Ltd., Hebei Topson Medical Technology Co., Ltd., Hunan VentMed Medical Technology Co., Ltd., Vivos Therapeutics, Inc., Guangdong Pigeon Medical Apparatus Co., Ltd., Nihon Kohden Corporation, Natus Medical Incorporated, SOMNOmedics GmbH, VYAIRE, Compumedics Limited, Drive DeVilbiss International, Nox Medical, eXciteOSA Inc., BPL Medical Technologies, Elmaslar Medikal A.S., BMC, and others.

Sleep Apnea Diagnostic Devices Market

Sleep Apnea Diagnostic Devices Market Insights, Competitive Landscape and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key sleep apnea diagnostic devices companies, including Natus Medical Incorporated., SOMNOmedics GmbH, Compumedics Limited, ZOLL Itamar Ltd., Nihon Kohden Corporation, Vyaire., Cleveland Medical Devices Inc., Cadwell Industries Inc., Koninklijke Philips N.V., InMode Aesthetic Solutions, ResMed, Resonea, DeVilbiss Healthcare LLC, Smiths Group Plc. (Smiths Medical), Hemodiaz Life Sciences Private Limited, ActiGraph, LLC, Advin Health Care, Recorders & Medicare Systems Pvt Ltd (RMS), Allengers, EB Neuro S.p.A., and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.